KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$11.86 USD
-0.25 (-2.06%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $11.84 -0.02 (-0.17%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Brokerage Reports
KalVista Pharmaceuticals, Inc. [KALV]
Reports for Purchase
Showing records 101 - 106 ( 106 total )
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
First HAE Candidate Unveiled; Reiterate Buy - Raising PT to $22
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Healthcare - Spotlight on HAE: Takeaways From Our KOL Discussion
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Force Is Strong with This One; Initiating with Buy - $20 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
The Force Is Strong with This One; Initiating with Buy - $20 PT
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.